DTP3 inhibitor

• CAT Number: I026580
• CAS Number: 1809784-29-9
• Molecular Formula: C26H35N7O5
• Molecular Weight: 525.61
• Purity: 98%
• Solubility: To be determined
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-((diaminomethylene)amino)pentanamide
• InChI: InChI=1S/C26H35N7O5/c1-16(34)31-22(15-18-9-11-19(35)12-10-18)25(38)32-20(8-5-13-30-26(28)29)24(37)33-21(23(27)36)14-17-6-3-2-4-7-17/h2-4,6-7,9-12,20-22,35H,5,8,13-15H2,1H3,(H2,27,36)(H,31,34)(H,32,38)(H,33,37)(H4,28,29,30)/t20-,21-,22-/m1/s1
• InChIKey: AOUZPXZGMZUQQS-YPAWHYETSA-N
• SMILES: O=C(N[C@H](CC1=CC=CC=C1)C(N)=O)[C@H](NC([C@H](NC(C)=O)CC2=CC=C(O)C=C2)=O)CCC/N=C(N)N

DTP3 inhibitor (CAT: I026580) is a targeted inhibitor of GADD45β/MKK7, effectively disrupting the cancer-selective NF-κB survival pathway. Through its selective action, DTP3 impedes the activation of NF-κB, a critical regulator of cell survival and inflammation. By specifically targeting GADD45β/MKK7, DTP3 offers a potential avenue to hinder the aberrant survival signaling pathways that contribute to cancer progression.

Reference

Tornatore L, Capece D, D’Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3. Toxicol Rep. 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006. PMID: 31080744; PMCID: PMC6502747.